FDA commissioner Marty Makary’s pledge came after Hims & Hers launched a compounded version of Novo’s Wegovy pill.

President Donald Trump has unveiled his TrumpRx website, offering over 40 drugs at steeply discounted prices to cash-paying ...

Medicine prices are facing increasing pricing pressure—and early 2026 is one of the first notable periods where the list ...

The London Cancer Hub will act as a global centre for cancer research as the UK looks to maintain competitiveness in the life ...

Bristol Myers Squibb (BMS) has reported full-year 2025 revenues of $48.2bn, essentially flat compared with $48.3bn in 2024.

Apotex and Grünenthal have finalised a licensing agreement granting Apotex exclusive Canadian rights to Nebido, a long-acting ...

Everest Medicines has signed an exclusive licence agreement with Micot to commercialise MT1013 in China and the Asia Pacific ...

After more than a year out in the cold, the programme’s reauthorisation is a boost for rare disease therapy developers.

PrimeGen US and DT Cloud Star Acquisition have entered a definitive merger agreement at an implied equity value of around $1.5bn.

Eisai will now take ownership of the Japanese rights to Henlius' differentiated anti-PD-1 therapy, Hetronifly (serplulimab).

The upcoming patent cliff, the impact of geopolitical and policy issues, and a changing deal environment were discussed at ...

Lilly anticipates revenue of between $80bn and $83bn in 2026 – a year that could see orforglipron enter the US market.